October 24, 2020
Business News

Humanigen Announces Lenzilumab in COVID-19 Program Updates


BURLINGAME, Calif.–()–Humanigen, Inc., (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate lenzilumab™, today announced updates on its lenzilumab in COVID-19 development program, including written guidance received from the US Food and Drug Administration (FDA) following a Type B meeting to obtain feedback on plans for an Emergency Use Authorization (EUA). FDA agreed that the Company’s intended submission may be sufficient to support an EUA request, subject to Phase 3 trial data, and provided guidance and support for the Company’s Biologics License Application and…



Click here to view the original article.

Related Posts

You might also like ...

Performant Announces Recently Launched Medicare Advantage Offering Exceeds Four Million Contracted Lives
Smart Mattress Market Analysis Highlights the Impact of COVID-19 2020-2024 | Increasing Penetration of Smartphones to Boost the Market Growth | Technavio
AON Splash Image
Daiya Healthcare Makes Big Waves in the Aloha State